Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in Infants and Young Children With ARPKD
2023-508217-17-00Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in autosomal recessive polycystic kidney disease (ARPKD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy: Percentage of subjects having renal replacement therapy (RRT) by 1 year of age. Started Apr 2024; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)
Beyond the preview
Go deeper on 2023-508217-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508217-17-00.